相关论文: In silico evaluation of pramlintide dosing algorit…

Current closed-loop insulin delivery algorithms need to be informed of carbohydrate intake disturbances. This can be a burden on people using these systems. Pramlintide is a hormone that delays gastric emptying, which enables insulin…

Modern treatments for Type 1 diabetes (T1D) use devices known as artificial pancreata (APs), which combine an insulin pump with a continuous glucose monitor (CGM) operating in a closed-loop manner to control blood glucose levels. In…

Simulation of post-prandial pharmacokinetics, such as muscle protein synthesis (MPS) through mTORC1 and insulin-induced glucose uptake, is often challenging due to the computational intensity of the multi-compartmental approach. In this…

This work presents a Model Predictive Control (MPC) for the artificial pancreas, which is able to autonomously manage basal insulin injections in type 1 diabetic patients. Specifically, the MPC goal is to maintain the patients' blood…

Background and objective: Hybrid automated insulin delivery (hAID) systems represent the most advanced therapy for type 1 diabetes (T1D). Current systems rely on linear or linearized models of glucose homeostasis, which may compromise…

In this paper, several advanced data-driven nonlinear identification techniques are compared on a specific problem: a simplified glucoregulatory system modeling example. This problem represents a challenge in the development of an…

We present the design and \textit{in-silico} evaluation of a closed-loop insulin delivery algorithm to treat type 1 diabetes (T1D) consisting in a data-driven multi-step-ahead blood glucose (BG) predictor integrated into a Linear…

Calculating mealtime insulin doses poses a significant challenge for individuals with Type 1 Diabetes (T1D). Doses should perfectly compensate for expected post-meal glucose excursions, requiring a profound understanding of the individual's…

In placebo-controlled randomized trials, the post-randomization use of concomitant medications may be higher in the placebo arm than in the treatment arm. This may dilute the full benefits of the randomized drug as estimated by the…

People with Type 1 diabetes (T1D) require regular exogenous infusion of insulin to maintain their blood glucose concentration in a therapeutically adequate target range. Although the artificial pancreas and continuous glucose monitoring…

In this paper, a novel robust tracking control scheme for a general class of discrete-time nonlinear systems affected by unknown bounded uncertainty is presented. By solving a parameterized optimal tracking control problem subject to the…

While the Artificial Pancreas is effective in regulating the blood glucose in the safe range of 70-180 mg/dl in type 1 diabetic patients, the high intra-patient variability, as well as exogenous meal disturbances, poses a serious challenge.…

We develop a new model of insulin-glucose dynamics for forecasting blood glucose in type 1 diabetics. We augment an existing biomedical model by introducing time-varying dynamics driven by a machine learning sequence model. Our model…

Diabetes mellitus is a global health crisis characterized by poor blood sugar regulation, impacting millions of people worldwide and leading to severe complications and mortality. Although Type 1 Diabetes Mellitus (T1DM) has a lower number…

Objective: The artificial pancreas (AP) has shown promising potential in achieving closed-loop glucose control for individuals with type 1 diabetes mellitus (T1DM). However, designing an effective control policy for the AP remains…

Diabetes cases worldwide have risen steadily over the past decades, lending urgency to the search for more efficient, effective, and personalized ways to treat the disease. Current treatment strategies, however, may fail to maintain…

Diabetes mellitus affects over 537 million adults worldwide. Insulin-dependent patients require continuous glucose monitoring and precise dose calculation while operating under strict power budgets on wearable devices. This paper presents…

Even though model predictive control (MPC) is currently the main algorithm for insulin control in the artificial pancreas (AP), it usually requires complex online optimizations, which are infeasible for resource-constrained medical devices.…

People living with Type 1 Diabetes (T1D) lose the ability to produce insulin naturally. To compensate, they inject synthetic insulin. One common way to inject insulin is through automated insulin delivery systems, which use sensors to…

People with type 1 diabetes (T1D) struggle to calculate the optimal insulin dose at mealtime, especially when under multiple daily injections (MDI) therapy. Effectively, they will not always perform rigorous and precise calculations, but…